Molecular Partners AG (MOLN) stock

MOLNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 12, 2026Score 1/30

$2.94−0.07 (-2.33%)

Close on Nov 13, 2026Market cap $118.70MP/E –Yield –

Molecular Partners revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

For fiscal 2025 it was CHF 0, down 100.0% from the year before. The highest annual figure on record is CHF 189.60M in fiscal 2022.

Period	Period end	Value	Change
FY2025	Dec 31, 2025	CHF 0	-100.0%
FY2024	Dec 31, 2024	CHF 4.97M	-29.4%
FY2023	Dec 31, 2023	CHF 7.04M	-96.3%
FY2022	Dec 31, 2022	CHF 189.60M	+1843.8%
FY2021	Dec 31, 2021	CHF 9.75M	+4.4%
FY2020	Dec 31, 2020	CHF 9.34M	-54.2%
FY2019	Dec 31, 2019	CHF 20.38M	–

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q2 FY2026	Jun 30, 2026	CHF 0	-100.0%
Q2 FY2025	Jun 30, 2025	CHF 0	–
Q2 FY2024	Jun 30, 2024	CHF 1.55M	–
Q2 FY2023	Jun 30, 2023	CHF 415.00K	–
Q2 FY2022	Jun 30, 2022	CHF 11.76M	–

Parsed from the XBRL in Molecular Partners's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is MOLN.

Revenue growth-100.0% · median -7.3%

Advertisement
300 × 250

See a number that looks wrong?